Get started
Author

Aurélie Swalduz

Observed names: A Swalduz, A. Swalduz, Aurelie Swalduz, Aurélie Swalduz, Swalduz, A., Swalduz, Aurelie, Swalduz, Aurélie
Observed institutions: Lyon 1 Université, Centre National de la Recherche Scientifique, Inserm, Université de Lyon, Centre Léon Bérard, Institute Cancer De La Loire Lucien Neuwirth, Centre de Recherche en Cancérologie de Lyon, UniCancer Group, Centre Hospitalier Universitaire de Saint-Étienne
ORCID: 0000-0002-8398-9373
Observed ORCIDs: 0000-0002-8398-9373, 0000-0003-0552-2118
OpenAlex ID: A5034021938
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR
2020 · Souad Assaad, Virginie Avrillon, et al. · European Journal of Cancer · 125
PDF
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer
2023 · Ali Chour, Julie Denis, et al. · Journal of Thoracic Oncology · 78
PDF
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
2022 · Anne-Laure Désage, Camille Léonce, et al. · Frontiers in Oncology · 65
PDF
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
2024 · Jessica J. Lin, Joshua C. Horan, et al. · Cancer Discovery · 64
Clinical Relevance of an Amplicon-Based Liquid Biopsy for DetectingALKandROS1Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer
2020 · Laura Mezquita, Aurélie Swalduz, et al. · JCO Precision Oncology · 51
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF -Mutant Metastatic Non–Small Cell Lung Cancer
2020 · Sandra Ortiz-Cuaran, Laura Mezquita, et al. · Clinical Cancer Research · 49
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
2021 · Oliver Illini, Maximilian Johannes Hochmair, et al. · Therapeutic Advances in Medical Oncology · 45
PDF
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.
2023 · Benjamin Besse, Christina S Baik, et al. · Journal of Clinical Oncology · 43
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)
2021 · Fabrizio Tabbò, Chiara Pisano, et al. · Cancer Treatment Reviews · 42
Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer
2022 · Sandra Ortiz-Cuaran, Aurélie Swalduz, et al. · European Journal of Cancer · 39
Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer
2020 · Elisa Gobbini, Aurélie Swalduz, et al. · Cancers · 36
PDF
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
2024 · Solange Peters, Shirish M. Gadgeel, et al. · Nature Medicine · 33
PDF
Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report
2022 · Alexia Gazeu, Mylena Aubert, et al. · Clinical Lung Cancer · 32
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
2021 · P. Heudel, S. Chabaud, et al. · ESMO Open · 32
PDF
Gene signature of circulating platelet‐bound neutrophils is associated with poor prognosis in cancer patients
2022 · Pacôme Lecot, Maude Ardin, et al. · International Journal of Cancer · 31
PDF
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
2022 · Oliver Illini, Hannah Fabikan, et al. · Therapeutic Advances in Medical Oncology · 31
PDF
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018
2023 · Olivier Bylicki, Pascale Tomasini, et al. · European Journal of Cancer · 26
The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience
2015 · Benoite Méry, Jean-Baptiste Guy, et al. · Critical Reviews in Oncology/Hematology · 24
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial
2024 · Olivier Bylicki, Florian Guisier, et al. · Lung Cancer · 23
PDF
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
2024 · Aurélie Swalduz, Michèle Beau-Faller, et al. · Lung Cancer · 21
1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours
2024 · A.E. Drilon, J.J. Lin, et al. · Annals of Oncology · 21
PDF
Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort
2021 · Laetitia Collet, Lidia Delrieu, et al. · Cancers · 21
PDF
Occupational asbestos exposure and survival among lung cancer patients
2023 · Hugo Noelle, Olivia Pérol, et al. · Lung Cancer · 19
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
2020 · Jordi Remon, Aurelie Swalduz, et al. · PLoS ONE · 18
PDF
Treatment sequences in EGFR mutant advanced NSCLC
2024 · M. Wespiser, A. Swalduz, et al. · Lung Cancer · 16
PDF
Works count: 183
Citation count: 1,323
H-index: 21
I10-index: 34
Year
Topic
Type